Please note: The information displayed on this page might be outdated.
Palladio Biosciences: Developer of novel therapeutics intended to develop medicines for orphan drug diseases of the kidney. The company's offerings include developing treatments for Polycystic Kidney Disease (PKD) which cause numerous fluid-filled cysts to grow in both kidneys, enabling doctors to prevent the progression of PKD.
US - Middle Atlantic
12 Penns Trail
Newtown, PA 18940
Newtown, PA 18940
Company Participants at Fall Private Company Showcase 2020
Palladio Biosciences, CEO
Mr. Martin is Chief Executive Officer of Palladio Biosciences, a clinical stage biopharmaceutical company developing medicines for orphan diseases of the kidney. Mr. Martin has more than 25 years of industry experience having previously served as Chief Executive Officer of Realm Therapeutics, which was acquired by ESSA Pharma where he is currently a director, Chief Operating Officer of Intercept Pharmaceuticals, and Chief Finance Officer at BioXell, which was acquired by Cosmo Pharmaceuticals. He began his career at SmithKline Beecham Pharmaceuticals where he held roles of increasing responsibility in marketing and business development and later joined Novartis as Vice President, Global Business Development & Licensing. He is an active coach and mentor to other senior executives, and is a guest lecturer at Wharton and Columbia Business School on biotech, entrepreneurship, and financing. Mr. Martin holds a BA from Cornell University and an MBA from Harvard.
Palladio Biosciences, Chief Financial Officer
Biotech financial and operations leader recognized for fundraising/ investor affinity, expert strategic, operational and financial leadership, and effective negotiating skills that result in the completion of significant, favorable corporate transactions. I am a collaborative cross-functional leader who possesses strong relationships in the biotech community with executives, investors, analysts, bankers and others. I have diverse leadership experience, in both publicly traded and private companies, with fundraising and capital strategy, M&A, financial and management reporting, FP&A, investing, systems and internal controls, supply chain strategy and execution and HR. I am nimble and resourceful with limited capital as well as effective in managing larger teams and resources, always with a tenacious focus on driving performance and delivering optimal financial and operational outcomes.